



(51) International Patent Classification:

A61K 9/107 (2006.01) A61K 9/48 (2006.01)
A61K 47/44 (2006.01) A61K 47/14 (2006.01)
A61K 9/16 (2006.01) A61K 31/58 (2006.01)
A61K 9/20 (2006.01) A23L 1/30 (2006.01)

(21) International Application Number:

PCT/EP2015/063606

(22) International Filing Date:

17 June 2015 (17.06.2015)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

14173067.1 19 June 2014 (19.06.2014) EP

(71) Applicant: SOLURAL PHARMA APS [DK/DK]; Ener-
givej 42, DK-2750 Ballerup (DK).

(72) Inventor: HØJGAARD, Bent; Morelvænget 5, DK-3450
Allerød (DK).

(74) Agent: LBKPATENT APS; Cobis Ole Maaløes Vej 3,
2200 Copenhagen (DK).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,

BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR,
KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG,
MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM,
PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC,
SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ,
TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU,
TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE,
DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU,
LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK,
SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments (Rule 48.2(h))

(88) Date of publication of the international search report:

11 February 2016

(54) Title: SOLID ORAL DOSAGE FORM OF LIPOPHILIC COMPOUNDS

(57) Abstract: The present invention relates to a pharmaceutical composition comprising compound having a log P of at least 5 and a vehicle, wherein the vehicle comprises (a) a fat component in an amount sufficient to achieve lymphatic absorption in a mammal, wherein the fat component is selected from a mono-glyceride of long chain fatty acids, a tri-glyceride of long chain fatty acids, and a mono- and tri-glyceride of long chain fatty acids.



WO 2015/193380 A3